AI-Powered Mammography Technology
Artificial intelligence for enhanced breast cancer detection
Company profile
Developing innovative medical technologies for women's health at every stage of life
Company profile
Hologic is a global medical technology company dedicated to improving women's health outcomes through innovative diagnostic and imaging solutions. Founded in 1985 and headquartered in the United States, Hologic operates in 36 countries with approximately 7,000 employees and holds over 4,100 patents. The company's mission centers on helping women live healthier lives by developing technologies that effectively detect, diagnose, and treat health conditions while raising the standard of care globally. Hologic's product portfolio spans multiple domains of women's health including breast health (mammography and imaging), gynecological health (surgical and diagnostic solutions), sexual health, skeletal health (bone density assessment), and body composition analysis. The company also operates a robust lab technologies division offering molecular diagnostics, cytology, oncology testing, and collection devices. During the COVID-19 pandemic, Hologic played a significant role in diagnostic testing, leveraging its molecular diagnostics capabilities. The company is committed to advancing women's health globally through its Global Access Initiative, philanthropy programs, and Project Health Equity. Hologic also created the Women's Health Index, an unprecedented research initiative studying the health and well-being of 3.9 billion women worldwide. The company emphasizes sustainability, quality, and innovation while working to break down barriers that prevent women from receiving necessary care. Hologic serves health systems, laboratories, clinics, and healthcare providers worldwide with a focus on delivering exceptional clinical results and patient outcomes.
Company description HOLOGIC official website
Mission. Women's health is more than a business, it is our purpose. We support women at every stage of life.
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Embedded · On Premise · Other deployment with recorded integration context.
Company milestones
April 2026: Blackstone and TPG completed acquisition of Hologic (go-private transaction). June 2026: Released 2025 Sustainability Report marking 40 years of impact. June 2026: Secured patent victory against Siemens Healthineers. May 2026: Presented new data at ASCO 2026 on Breast Cancer Index Test. April 2026: Published new evidence on AI-powered mammography technology.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Artificial intelligence for enhanced breast cancer detection
Personalized genomic test for breast cancer treatment decisions
Sample collection device for molecular diagnostics
Bone density measurement technology for osteoporosis screening
Molecular diagnostics platform for infectious disease testing
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
No linked records are currently available.
Clinical validation
No linked records are currently available.
Regulatory
K243341 · 510k · Jul 31, 2025
Genius Digital Diagnostics System with the Genius Cervical AI algorithmDEN210035 · De Novo · Jan 31, 2024
Genius AI Detection 2.0 with CC-MLO CorrelationK230096 · 510k · May 23, 2023
Genius AI Detection 2.0K221449 · 510k · Oct 6, 2022
Genius AI DetectionK201019 · 510k · Nov 18, 2020
QuantraK163623 · 510k · Oct 20, 2017
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Global HIV testing and treatment programs
Breast cancer detection technology
Hologic Costa Rica operations
Personalized breast cancer survivorship care using Breast Cancer Index Test
Enabled personalized treatment decisions for extended endocrine therapy beyond one-size-fits-all approach
World-class quality culture and operational excellence
Earned prestigious Shingo Prize for culture of excellence and world-class results
05 · Leadership
Leadership profiles and professional links from the current Company record.
Steve MacMillan
President and CEO
Malik Khan
Corporate Vice President of Quality
Mireille Akilian
Vice President of R&D
Tanja Brycker
Executive (Data, Technology and AI)
Sami Diab
Associate Medical Director
Michelle Janisch
Vice President
Erica Wheeler
Executive (Cervical Cancer Prevention)
06 · Company updates
Recent articles published on HOLOGIC's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.